Yousif Capital Management LLC Cuts Holdings in Insulet Co. (NASDAQ:PODD)

Yousif Capital Management LLC reduced its position in Insulet Co. (NASDAQ:PODD) by 25.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,607 shares of the medical instruments supplier’s stock after selling 3,609 shares during the period. Yousif Capital Management LLC’s holdings in Insulet were worth $2,302,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Parkside Financial Bank & Trust increased its stake in Insulet by 251.0% in the 3rd quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 123 shares in the last quarter. Allworth Financial LP increased its stake in Insulet by 104.5% in the 3rd quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 92 shares in the last quarter. Wolff Wiese Magana LLC increased its stake in Insulet by 2,680.0% in the 4th quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 134 shares in the last quarter. BluePath Capital Management LLC purchased a new position in Insulet in the 3rd quarter valued at approximately $31,000. Finally, Lindbrook Capital LLC increased its stake in Insulet by 64.1% in the 4th quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock valued at $42,000 after purchasing an additional 75 shares in the last quarter.

Insider Activity at Insulet

In related news, Director Shacey Petrovic sold 11,609 shares of Insulet stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the transaction, the director now owns 2,567 shares in the company, valued at $418,215.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.47% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. JPMorgan Chase & Co. raised their price objective on Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd. Barclays lowered their target price on Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a report on Monday, February 26th. Piper Sandler lowered their target price on Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a report on Friday, February 23rd. Finally, Stifel Nicolaus increased their target price on Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a report on Monday, February 5th. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $243.21.

Insulet Price Performance

PODD stock opened at $171.94 on Wednesday. Insulet Co. has a 52-week low of $125.82 and a 52-week high of $335.91. The stock has a market capitalization of $12.04 billion, a price-to-earnings ratio of 59.09, a price-to-earnings-growth ratio of 3.07 and a beta of 0.98. The company has a quick ratio of 2.62, a current ratio of 3.51 and a debt-to-equity ratio of 1.86. The stock’s fifty day simple moving average is $171.09 and its 200-day simple moving average is $180.25.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.73. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The firm had revenue of $509.80 million for the quarter, compared to analysts’ expectations of $461.26 million. During the same quarter last year, the firm earned $0.55 earnings per share. The firm’s revenue for the quarter was up 37.9% compared to the same quarter last year. Equities research analysts expect that Insulet Co. will post 3.08 EPS for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.